| Cheryl C Hamblin, SLP | |
|
3171 Beaver Vu Dr Ste B, Beavercreek, OH 45434 | |
| (850) 543-6545 | |
| Not Available |
| Full Name | Cheryl C Hamblin |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3171 Beaver Vu Dr Ste B, Beavercreek, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477571354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2202004594 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cheryl C Hamblin, SLP 3171 Beaver Vu Dr Ste B, Beavercreek, OH 45434-6368 Ph: (850) 543-6545 | Cheryl C Hamblin, SLP 3171 Beaver Vu Dr Ste B, Beavercreek, OH 45434 Ph: (850) 543-6545 |
News Archive
Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.
University of Michigan researchers have determined how a gene that is known to be defective in Down syndrome is regulated and how its dysregulation may lead to neurological defects, providing insights into potential therapeutic approaches to an aspect of the syndrome.
Maxim Pharmaceuticals have announced the United States Patent and Trademark Office issued U.S. patent number 6,828,091 B2, entitled "Method of Identifying Immunosuppressive Agents."
› Verified 4 days ago
Sara Raye Ditzel, MSP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3817 Colonel Glenn Hwy, Beavercreek, OH 45324 Phone: 937-427-9200 | |
Lea Ann Hinkle, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2942 Dayton Xenia Rd, Beavercreek, OH 45434 Phone: 937-429-7588 | |
Kimberlyn Cooper-miller, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3817 Colonel Glenn Hwy, Beavercreek, OH 45324 Phone: 937-427-9200 Fax: 513-755-3762 | |
Megan Strum, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2498 Dayton Xenia Rd, Beavercreek, OH 45434 Phone: 937-427-1919 | |
Ms. Jeannine Danis, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3560 Kemp Rd, Beavercreek, OH 45431 Phone: 937-429-7610 | |
Ms. Adrienne Mann, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3817 Colonel Glenn Hwy, Beavercreek, OH 45324 Phone: 937-427-9200 | |
Julia Laughman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3817 Colonel Glenn Hwy, Beavercreek, OH 45324 Phone: 937-427-9200 |